spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

New Study Demonstrates: WACKER’s Antioxidant HTEssence® Lowers LDL Cholesterol Significantly

Munich/Las Vegas, September 27, 2017

At Supply Side West 2017, WACKER is presenting new results on the effect of its nature-identical hydroxytyrosol HTEssence® on heart health. A recent human clinical study demonstrates that HTEssence® is able to significantly reduce LDL (low density lipoprotein) cholesterol. Reducing LDL has been found to support heart health. Hydroxytyrosol is a highly effective antioxidant found in olives with positive effects on blood pressure, joints and the immune and cardiovascular systems. WACKER is producing the first nature-identical hydroxytyrosol free of unwanted byproducts and with a defined amount of active ingredient. HTEssence® offers an excellent price/performance ratio and is easy to process in dietary supplements and functional beverages. WACKER will be exhibiting this product at SupplySide West in Las Vegas, Nevada (USA), from September 27-29, 2017.

Hydroxytyrosol, a secondary plant metabolite, is considered a highly effective antioxidant. Reportedly, it strengthens the immune system, lowers blood pressure, reduces inflammation and improves bone and joint health. Above all, it is said to have a positive effect on blood lipid management, an effect that – according to the US National Cholesterol Education Program (NCEP) – can support a healthy heart.

A recent clinical study has now shown that WACKER’s nature-identical hydroxytyrosol HTEssence® has a positive effect on blood cholesterol. In a  randomized, double-blind, placebo-controlled crossover study, 30 healthy volunteers consumed 30 mg of hydroxytyrosol per day for a total of four weeks with two weeks washout between treatments. The hydroxytyrosol was supplemented either as HTEssence® or as olive extract in comparison to placebo.

Results show a significant reduction of LDL cholesterol in the blood plasma by 9.4 mg/dL (-8%) with HTEssence® (see Figure 1). High LDL levels are one main factor for the occurrence of coronary heart diseases and arteriosclerosis. The NCEP estimates that each one percent reduction in LDL cholesterol reduces the risk of heart disease by one to two percent (see Figure 2). Accordingly, an LDL cholesterol reduction of eight percent may reduce the risk for heart diseases by eight percent or more.

Due to its diverse modes of action, hydroxytyrosol is a popular ingredient in dietary supplements. One drawback, until recently, was the way it was produced. In nature, hydroxytyrosol is found in olives and olive leaves and its extraction is complex and cost-intensive. But with WACKER’s patented process, it is possible to synthesize a nature-identical substance of much greater purity, free of unwanted byproducts, and with a defined amount of active ingredient. Available as an odorless, water-soluble powder and liquid, the product is suitable for use in functional foods and dietary supplements, such as tablets, capsules, energy bars and functional beverages.

Further WACKER highlights at SupplySide West:

  • Dispersible curcumin and CoQ10 with high bioavailability
Cyclodextrins can considerably enhance the body’s absorption of non-bioavailable active ingredients. With the aid of gamma-cyclodextrin, curcumin’s bioavailability can be increased by a factor of around 40 compared to conventional turmeric extracts, as shown in a recent clinical study. Likewise, the bioavailability of coenzyme Q10 can be increased 18-fold by complexing it with gamma-cyclodextrin.

  • Vegan L-cystine and L-cysteine based on fermentation
The naturally occurring amino acids L-cysteine and L-cystine are often used in nutritional supplements for various functions, such as skin whitening, as an antioxidant and for stronger hair and nails. Traditionally, cysteine is extracted from human or animal sources such as hair, feathers and pig bristles using hydrochloric acid. Replacing this method with biotechnology, WACKER produces L-cystine and L-cysteine using a patented fermentation process. As a result, WACKER’s products are halal, kosher and purely vegan.

  • Alpha-cyclodextrin: a dietary fiber with a health claim
Alpha-cyclodextrin is a water-soluble source of fiber that WACKER produces enzymatically from renewable raw materials such as corn or potato starch. It is scientifically proven to regulate blood sugar after high-starch meals – an effect that has been confirmed by the European Food Safety Authority (EFSA). This makes alpha-cyclodextrin particularly suitable as a dietary supplement.

Visit WACKER at SupplySide West 2017 – Booth I133.



Figure 1: Results of a recent clinical human study show a significant reduction of LDL cholesterol with WACKER’s nature-identical hydroxytyrosol HTEssence® in comparison to olive extract and placebo (chart: Wacker Chemie AG).



Figure 2: High LDL (low density lipoprotein) levels are one main factor for the occurrence of coronary heart diseases and atherosclerosis. WACKER’s HTEssence® is able to significantly reduce LDL (chart: Wacker Chemie AG).

For further information, please contact:
Wacker Chemie AG
Media Relations & Information
Nadine Baumgartl
Tel. +49 89 6279-1604
nadine.baumgartl@wacker.com
www.wacker.com

The company in brief:
WACKER is a globally active chemical company with some 13,450 employees and annual sales of around €4.6 billion (2016, excluding Siltronic).
WACKER has a global network of 23 production sites, 19 technical competence centers and 49 sales offices.

WACKER SILICONES

Silicone fluids, emulsions, rubber and resins; silanes; pyrogenic silicas; thermoplastic silicone elastomers

WACKER POLYMERS
Polyvinyl acetate and vinyl acetate co- and terpolymers in the form of dispersible polymer powders, dispersions, solid resins and solutions

WACKER BIOSOLUTIONS
Biotech products such as cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins

WACKER POLYSILICON
Polysilicon for the semiconductor and photovoltaic industries
 
Print this page
Send to a friend
   
spacer
News and Press Releases

YHEC announces the promotions of Michelle Jenks and Rachael McCool to the role Project Director

YHEC is pleased to announce the promotions of Michelle Jenks from the Economic Modelling team and Rachael McCool from the Systematic Reviewing team to the role Project Director. Michelle has a Master’s degree (MSc) in health economics from the University of York and has conducted economic evaluations and systematic reviews for both public and private sector clients. Michelle is the lead modeller in YHEC’s role as an External Assessment Centre for NICE and has also led on a range of economic evaluations conducted for clients within industry, such as cost-utility models and budget impact models. She often leads the development of early economic analyses to inform clinical trial design and pricing strategy.
More info >>


White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

Industry Events

Clinical Trial Supply New England 2018

7-8 March 2018, Boston, MA, USA

Clinical Trial Supply New England has now reached its 7th birthday! For the 7th annual Clinical Trial Supply New England 2018 conference, we have speakers who will focus primarily on discussing case studies, drawing from their own experiences to share the highs and lows for you to adopt in your trials.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement